Completed PHASE1 INTERVENTIONAL 3-arm NCT00688272

Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag

A Phase I, Double-blind, Placebo and Observer-blind Positive Controlled, Randomized, Parallel Group Study in Healthy Subjects to Investigate the Photoirritant Potential of Eltrombopag

Sponsor: GlaxoSmithKline

Conditions Purpura, Thrombocytopaenic, Idiopathic

Interventions Ciprofloxacin Eltrombopag Placebo

Updated 7 times since 2017 Last updated: Nov 13, 2017 Started: Jun 2, 2008 Primary completion: Sep 25, 2008 Completion: Sep 25, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Purpura, Thrombocytopaenic, Idiopathic and is currently completed. GlaxoSmithKline leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Dec 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Dec 2017 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dundee, United Kingdom